Skip to main content

Table 1 Clinical summary of patients with pre-existing Hepatitis B and C treated with ipilimumab

From: Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series

Case No. Age (yrs) Sex Liver metastases? Type of Hepatitis Evidence of liver fibrosis? Therapy for metastatic melanoma prior to ipilimumab LFTs prior to administration of ipilimumab Change in LFTs during Ipilimumab Best Response to Ipi Comments
1 65 M N HCV (active) Y High dose Interleukin-2 Gr 1 AST, Gr 1 ALT None PD HCV viral load increased four-fold after IL-2, ipilimumab and temozolomide
2 56 M N HCV (active) Unknown Stereotactic Radiotherapy, then WBRT AST & ALT WNL None PD Possible drug-related hepatitis detected 2 months after receiving 4 doses of ipilimumab
3 43 M N HCV (active) N Temozolomide Gr 2 AST, Gr 2 ALT Normalized by cycle 4 Mixed response HCV viral load decreased to undetectable levels after 4 doses of ipilimumab
4 71 M N HCV (active) Y None Gr 1 AST, Gr 1 ALT Gr 2 AST, Gr 3 ALT after cycle 3 SD HCV viral load decreased 5-fold to 408,000 IU/mL after 3 doses of ipilimumab; ocular melanoma
5 56 M (multiple tumors involving 25-75% of liver, largest = 6.4 cm) HBV (inactive) Unknown None Gr 1 AST, ALT WNL None PD Concurrent administration of entecovir for prophylaxis against HBV reactivation
6 60 M N HBV (active) Unknown high-dose interleukin-2, talimogene laherparepvec and dacarbazine AST & ALT WNL None PD Tenofovir administration prior to ipi brought HBV viral load from 2950 to 41 IU/mL; became undetectable and remained so throughout ipilimumab
7 42 F (multiple tumors involving 30-40% of liver, largest = 2.7 cm) HBV (inactive) Unknown None AST & ALT WNL None PD HBV viral load undetectable prior to starting ipilimumab
8 56 M N HBV (active) Unknown None AST & ALT WNL None PD Entecavir administration prior to ipi brought HBV viral load from 9560 to 454 IU/mL; became undetectable and remained so throughout ipilimumab
9 71 M N HBV (active) Cirrhosis noted on CT; no confirming path findings None Gr 1 AST, ALT WNL None SD HBV viral load 700 IU/mL prior to starting ipilimumab
  1. Table 1 (Gr, Grade of toxicity as measured by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; AST, aspartate aminotransferase; ALT, Alanine aminotransferase; LFT, Liver function tests; PD, Progressive disease; Ipi, ipilimumab; SD, Stable disease)).
Back to article page